Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG-NSA (Polyglycerol-based Nanostructured Organic Sheet) is a synthetic, two-dimensional nanomaterial designed as a therapeutic platform to treat radiation-induced mucositis. These nanosheets are functionalized with CD63-targeting aptamers, which allow them to selectively capture and sequester small extracellular vesicles (sEVs) released by damaged tissues. By removing these vesicles, which carry inflammatory triggers such as double-stranded DNA, PG-NSA prevents the activation of the STING (stimulator of interferon genes) pathway in macrophages, thereby suppressing excessive inflammation. Additionally, the polyglycerol structure of the nanosheet inherently scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS), providing a multi-modal anti-inflammatory effect. Its unique sheet-like geometry offers a significantly higher surface area and binding capacity for vesicles compared to traditional spherical nanoparticles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PG-NSA.